KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hims & Hers Health (HIMS) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Hims & Hers Health (HIMS) over the last 6 years, with Sep 2025 value amounting to $345.8 million.

  • Hims & Hers Health's Cash & Equivalents rose 108.91% to $345.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.8 million, marking a year-over-year increase of 108.91%. This contributed to the annual value of $220.6 million for FY2024, which is 128.20% up from last year.
  • Per Hims & Hers Health's latest filing, its Cash & Equivalents stood at $345.8 million for Q3 2025, which was down 69.25% from $1.1 billion recorded in Q2 2025.
  • Hims & Hers Health's Cash & Equivalents' 5-year high stood at $1.1 billion during Q2 2025, with a 5-year trough of $46.8 million in Q4 2022.
  • In the last 3 years, Hims & Hers Health's Cash & Equivalents had a median value of $129.3 million in 2024 and averaged $239.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 7,633.13% in 2021, then tumbled by 48.64% in 2022.
  • Quarterly analysis of 5 years shows Hims & Hers Health's Cash & Equivalents stood at $71.8 million in 2021, then tumbled by 34.84% to $46.8 million in 2022, then soared by 106.67% to $96.7 million in 2023, then surged by 128.20% to $220.6 million in 2024, then surged by 108.91% to $345.8 million in 2025.
  • Its Cash & Equivalents stands at $345.8 million for Q3 2025, versus $1.1 billion for Q2 2025 and $273.7 million for Q1 2025.